Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of nivolumab plus intravesical BCG versus BCG alone in high-risk non-muscle-invasive bladder cancer after prior BCG
MOH_2020-06-23_009067Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) comparing Nivolumab + BCG with BCG alone (2 arms). Started Apr 2020; status: completed.
02
Drugs
nivolumabbcg vaccine
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on MOH_2020-06-23_009067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-23_009067.